Oramed Pharmaceuticals
ORMP
88 hedge funds and large institutions have $31M invested in Oramed Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 34 closing their positions.
275% more call options, than puts
Call options by funds: $854K | Put options by funds: $228K
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
6.52% less ownership
Funds ownership: 23.64% → 17.12% (-6.5%)
15% less funds holding
Funds holding: 103 → 88 (-15)
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
60% less capital invested
Capital invested by funds: $78.4M → $31M (-$47.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.48M |
| 2 |
Renaissance Technologies
New York
|
+$1.92M |
| 3 |
JP Morgan Chase
New York
|
+$1.7M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.33M |
| 5 |
E
Ergoteles
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.04M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.33M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.92M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.63M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.62M |
ORMP Hedge Fund Activity: Q2 2022 in Review
88 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2022, worth a combined $31M — down 60% from $78.4M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ORMP and 20 opened new positions — a net loss of 14 holders — while 19 trimmed existing stakes and 24 added.
The largest buyer was Citadel Advisors, adding an estimated $2.48M. The largest seller was BlackRock, cutting an estimated $9.04M.
- 88 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2022, down from 103 in Q1 2022.
- Funds reported $31M of Oramed Pharmaceuticals stock for Q2 2022, down 60% quarter-over-quarter.
- 20 funds opened new Oramed Pharmaceuticals positions in Q2 2022 and 34 closed out, a net change of -14 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $2.48M added.
- The largest Oramed Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $9.04M sold.
Based on aggregated 13F filings for Q2 2022.